ImmuPharma deal on peptide technology as a vector for cancer radiotherapy with Orano

6 March 2023
immupharma_large

UK-based drug developer ImmuPharma (LSE: IMM) has signed an initial collaboration agreement on the company's peptide technology, with Orano.

The news sent ImmuPharma shares up 6.8% trading to 2.44 pence per share early this morning, but the stock was down 2% at 2.24 pence by early afternoon.

Orano, a French nuclear fuel cycle specialist, has paid a small undisclosed amount to ImmuPharma for a 12-month collaboration to identify suitable radiotherapy candidates for the treatment of cancer. ImmuPharma has agreed to provide its peptide technology, to explore the potential to allow delivery of a potent radioactive isotope to the core of a cancer cell.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical